Hospital

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.

Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.

Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

The Center for Innovation & Value Research has released a final report recommending strategies to ensure health equity is integrated into health technology assessment, which can influence drug pricing and selection by payers, as well as patient access to drugs.

Educators describe a project where they used TikTok to encourage students to develop innovative informatics and medication safety technologies for fun, engaging learning.

OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.

P043 is currently approved for patients 6 years and older with moderate to severe persistent allergic asthma whose disease is inadequately controlled with inhaled corticosteroids.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

The hospital pharmacists’ role in treating patients with epilepsy starts with their place on the multidisciplinary team, which identifies appropriate drug selection in the hospital. It continues with counseling and therapy reconciliation to assure smooth transitions upon patient discharge to the community.

Jose Tinajero, PharmD, BCOP, discusses the results of a retrospective study evaluating patients with B-cell acute lymphoblastic leukemia.

Bezisterim, an anti-inflammatory insulin sensitizer, will be authorized to proceed to a phase 2 clinical trial.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Pharmacy students discuss how they use social media platforms like TikTok, Instagram, and YouTube to reinforce their classroom learning.

Myasthenia gravis is a chronic autoimmune disease that causes muscle weakness and fatigue, with 4 main treatment options available.

Cases have been detected in 33 US states so far this year, and the virus has recently hospitalized the former Chief Medical Advisor to the President of the US Anthony Fauci.

For those with unexplained pregnancy loss, these results could prove promising improvements to birth outcomes.

Women's health extends beyond reproductive health, yet much of the research in women's health focuses on these "below the belt" health issues, despite data showing that women disproportionately suffer from certain health conditions, such as heart failure.

Shared clinical decision-making presented drawbacks, resulting in age-based recommendations for adults aged 75 years and older and risk-based recommendations for individuals aged 60-74 years.

An examination of the 340B Drug Pricing Program's original intent, current challenges, and potential resolutions in today's complex health care landscape.

The author suggest how to improve the representation of women, older adults, and minorities in clinical research that will require effort from a broad range of stakeholders.

Although small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) share many of the same symptoms, SIBO affects the small intestine and IBS affects the large intestine.

The application includes data from the Vivacity-MG3 study, demonstrating that individuals who received the drug had superior outcomes compared with the standard of care alone.

The findings further the understanding of respiratory virus immune evasion mechanisms and uncover how RSV-NS1 can target therapeutic intervention

Pharmacists can provide extra resources for patients, including explanations of the therapy options for the patients, the course of therapy, and what patients can expect.

Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.